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Methods: CHF was induced in two groups of male mongrel dogs by rapid right ventricu- 
lar pacing at 240 beats per minute for 10 days. In an acute experiment cardiorenal 
parameters were measured in clearances at baseline and with two doses of BAY 41. 
2272 (2 and 10 microgramlkgimin; N=8) and NTG (1 and 5 microgramlkgimln; N=6), 
respectively. Data are expressed as mean * SEM. * indicates a p-value ~0.05. 
Results: BAY 41.2272 reduced mean arterial pressure (from 113*8 to 107*7 and 942.6. 
mmHg), pulmonary artery pressure (from 29+2 to 27+2 and 25*2’ mmHg), pulmonary 
capillary wedge pressure (from 25r2 to 22+2 and 20*2’ mmHg), and increased cardiac 
output (from 2.1*0.2 to 2.2e.03 and 2.3i0.2’ L/mm) and renal blood flow (from 131 +I7 to 
145+18’ and 162+18’ mUmIn). Plasma renin activity, angiotensin II, aldosterone, and 
glomerular filtration rate remamed unchanged. These properties were qualitatively Identi- 
cal to those of NTG. In contrast, whereas NTG reduced right atrial pressure (from 
8.4*1.3 to 7.6kl.3’ and 6.4+1.31 mmHg), it remained unchanged wth BAY 41.2272. Fur- 
thermore, in contrast to NTG, BAY 41-2272 slightly but significantly increased urine flow 
(from 0.10*0.02 to 0.11*0.02 and 0.19iO.04’ mUmin). 
Conclusion: BAY 41-2272 in this experimental model of CHF resulted in beneficial car- 
diac unloading actions. Unlike NTG, it did not reduce right atrial pressure and it acted pri- 
manly as an arterial vasodilator. These characteristics make BAY 41-2272 a promising 
new drug for indications like congestive heart failure, coronary artery disease, and arte- 
rial hypertension. 
inhibition was greater in female cells (~~0.05 compared with males). 
Conclusion: Genistein increases contraction in male, but not female, cardiac myocytes. 
This may be due to a shortened APD and greater block of I ca,L in female myocytes. 
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Rock, AR 
Background: Increasing evidence shows that growth factors, especially transforming 
growth factor-p, (TGF-P,). can protect myocardium from ischemia-reperfusion (I-R) 
injury. Recent studies suggest that matrix metalloproteinases (MMPs) and NADPH OXI- 
dase are involved in myocardial I-R injury. The present study was designed to examme 
the modulation of MMP-1 and NADPH oxidase in the cardioprotective role of TGFQ, dur- 
ing I-R. Materials and Methods: Sprague-Dawley (SD) rats were subjected to 1 hr of 
myocardial &hernia [total left coronary artery (LCA) ligation] followed by 1 hr of reperfu- 
sion (n=9). Parallel groups of rats were pretreated with recombinant TGF-P, (rTGF-P,, 4 
“g/kg. n=9) before reperfusion. or exposed to sham I-R (control group, n=8). After reper- 
fusion, infarct size was determined by Evan bluefIX staining. Besides continuous 
hemodynamic monitoring, MMP-1, p67phox (a subunit of NADPH oxidase), lipid peroxi- 
dation were quantified in I-R myocardial tissues. Results: I-R caused myocardial necro- 
sis and dysfunction indicated by decrease in dp/dt, mean arterial blood pressure and 
heart rate (all PcO.01 vs. sham control group). Simultaneously, expression of MMP-1 and 
p67phox subunit of NADPH oxidase and lipid peroxidation all increased in I-R regions (all 
P<O.Ol vs. sham control group). Importantly, treatment of rats with rTGF-P, reduced the 
extent of myocardlal necrosis and dysfunction despite I-R (all P<O.Ol). rTGF-P, treat- 
ment also inhibited the upregulation of MMP-1 and attenuated lkpid peroxidation and 
p67phox NADPH oxidase expression in the I-R myocardium (all P&05). Conclusion: 
The present study shows that rTGF-P, protects the myocardium from I-R. The effect 
TGF-P, on rep&&ion injury is associated with attenuation of expression of MMP-1 and 
p67phox NADPH oxidase. and lipid peroxidation. 
1082-l 50 Sex Differences in the Response of Cardiac Myocytes to 
the Phytoestrogen, Genistein 
Reoinald Liew, Mark Stagg, Peter Collins, Kenneth T. MacLeod, National Heart and Lung 
Institute, Imperial College, London, United Kingdom 
Background: The soy-phytoestrogen, genistein, appears to be cardioprotective, 
although the relative benefits for man and women are unknown. We tested the hypothe- 
SIS that genistein produces different actions on male and female myocytes. 
Methods: Lefl ventricular myocyte?., isolated from weight-matched male and female 
gumea-pigs, were field stimulated (1 Hz, 37 “C) in a superfusion chamber. Genistein- 
induced changes in cell shortening and the calcium transient were recorded. The effects 
of genisteln on the action potential duration at 50 and 90% repolarization (APD, and 
APD,,, respectively) and the peak L-type calcium current (&) were measured. 
Results: Genisteln increased cell shortenmg in male myocytes at 10 and 4OpM, whilst 
decreasing shortening in female myocytes at 1 pM. 
*p-Q Q5 
Gemstein also increased the calcium transients in male myocytes, but produced little 
effect in female myocytes. 40 phi genistem shortened APD,, in female myocytes from 
329 * 24 ms (mean * SEM) to 245 f 21 ms (n=29, pcO.001) and APD,, from 398 * 25 
ms to 299 * 19 ms (p<O.OOl, n=29), bbt did not significantly affect APD in male myocytes 
(1x22). Furthermore, although 40 &M genistein inhibited ICa,L in both male and female 
myocytes by 47 * 4% (n=23, p&001) and 59 * 3% (ng27, pcO.001) respectively, the 
1082-l 51 Raloxifene Acutely Suppresses Ventricular Myocyte 
Contractility Through Inhibition of the L-Type Calcium 
Current 
Reginald Liew, Mark Stagg. Kenneth T. MacLeod, Peter Collins, National Heart and Lung 
Institute, Imperial College, London, United Kingdom 
Background: The selective estrogen receptor modulator, raloxifene (Ral). is widely used 
in the treatment of postmenopausal osteoporosis. but mav also be cardioorotective. We 
investigated whether it affects myocyte contractility in a similar way to 17P_estradiol. 
Methods: We studied the direct actions of Ral on cell shortenino and the calcium fCa) / 
transient in field-stimulated (1 Hz, 37 “C) left ventricular myocytes isolated from male 
guinea-pigs. The effects of 1 wM Ral were assessed before and after myocyte incubation 
with the specific estrogen receptor antagonist, ICI 182,780 (10 fl) and the nitric oxide 
synthase inhibitor, L-NAME (100pM). Action potential duration (APD) and the L-type Ca 
current (&) were measured using switch-clamptng. 
Results: Ral inhibited cell shortening and the Ca transient in a concentration dependent 
manner. 1 ]IM Ral decreased cell shortening by 33 f 2% (mean * SEM, p<O.OOl. n=l4) 
and the Ca transient by 24 * 2% (p<O.OOl) compared with control values. These Ral- 
induced changes were abolished after incubation with ICI 182,780 (n=ll). whilst incuba- 
tion with L-NAME was without effect (n=l3). 1 FM Ral decreased the time to 90% APD 
repolarisation from 89 * 1% of total APD to 78 * 5% (~~0.05, n=27) and the peak Ica,L by 
59 f 6% (pcO.001, n=8). 
Conclusion: Ral directly suppresses ventricular myocyte contractility at physiologlcal 
concentrations through inhibition of ba,L This appears to be mediated via the estrogen 
receptor and may explain some of the cardioprotective actions of Ral. 
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Prapti M. Kanani, Dawn C. Thomas, David S. Freedman, Janine E. Janosky, Patricia K. 
Agatisa, Trevor J. Orchard, Children’s Hospital of Pittsburgh, Pittsburgh, PA 
Background: Children with FH merit early therapeutic interventions to prevent premature 
coronary heart disease. We studied the effects of simvastatin and antioxidant vitamms on 
lipid levels and on the lipoprotein subclasses in children with FH. Methods: 10 children (8 
boys, 2 girls) with FH, age 10 to 18 years, have so far completed a double-blind, random- 
ized, cross-over trial with wtamins and statin therapy. Baseline measurements included a 
chemical fasting llpid profile and nuclear magnetic resonance (NMR) spectroscopy to 
study lipoprotein subclasses. Pabents were randomly assigned to 20 mg simvastatin or a 
combination of 400 IU Vitamin E +lOOO mg Vitamin C daily for 12 weeks. Subjects then 
“crossed over” to the other treatment for three months, after which above measurements 
were repeated. A final measurement was performed after withdrawal of all treatment for 
three months. Liooorotein chanaes for both treatments were analvzed bv reoeated mea- , ,. 
sures ANOVA with pcO.05 considered statistically significant. Results: At baseline, chem- 
lcallv measured mean total cholesterol fTCl was 250 maldl. LDL 186 moldl. HDL 35 and 
triglycerides (TG)l46mg/dl. After statin therapy, mean TC decreased by 27% (p= O.Ol), 
LDL 34% (p=O.Ol), TG 27% (p=O.O3) while HDL Increased 8% (p=O.39). NMR measure- 
ments showed an increase in HDL particle size (p=O.Ol), decrease in LDL particle con- 
centration (p=O.OOl) and a trend towards increase in LDL particle size. In contrast, after 
vitamins, there was negligible change from baseline in chemically measured TC (O%), 
LDL(-3%), some change in HDL (+5%). wth a trend towards increase in TG (34%). NMR 
showed a significant decrease in LDL (p=O.b2) and HDL size (p=O.Ol) and a decrease in 
the amount of large HDL (p=O.O3). Conclusions: In our study, vitamins lowered the 
amount of protective large HDL, and decreased both HDL and LDL size, increasing 
atherogenic lipoproteins. In contrast, simvastatin therapy raised HDL size in addition to 
lowering LDL partlcle concentration. These results in children with FH support the fmd- 
ings from the HATS study that anttoxidant vitamin therapy may adversely affect lipopro- 
tern distribution. 
